Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets …

J Shepherd, P Barter, R Carmena, P Deedwania… - Diabetes …, 2006 - Am Diabetes Assoc
OBJECTIVE—The Treating to New Targets study showed that intensive lipid-lowering therapy
with atorvastatin 80 mg/day provides significant clinical benefit beyond that afforded by …

Atherogenic lipoprotein particles in atherosclerosis

R Carmena, P Duriez, JC Fruchart - Circulation, 2004 - Am Heart Assoc
The importance of low-density lipoprotein (LDL) cholesterol in the development of atherosclerosis
has long been recognized, and LDL cholesterol remains the primary target of therapy …

Diagnosing insulin resistance by simple quantitative methods in subjects with normal glucose metabolism

…, JT Real, RI Lorente, A Priego, R Carmena - Diabetes …, 2003 - Am Diabetes Assoc
OBJECTIVE—To identify a reliable yet simple indirect method for detection of insulin
resistance (IR). RESEARCH DESIGN AND METHODS—A total of 65 subjects (44 men and 21 …

Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study

P Deedwania, P Barter, R Carmena, JC Fruchart… - The Lancet, 2006 - thelancet.com
Background Despite the prognostic value of metabolic syndrome for predicting cardiovascular
events, few trials have investigated the effects of statin therapy on cardiovascular …

Abdominal obesity, insulin resistance, and metabolic syndrome in a southern European population

…, RI Lorente, J Martı́nez-Valls, R Carmena - European journal of …, 2003 - Elsevier
Background: Our objective was to investigate the relationship between abdominal obesity (AO),
as measured by waist circumference (WC), insulin resistance (IR), and components of …

Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: results of the CLAMORS Study

J Bobes, C Arango, P Aranda, R Carmena… - Schizophrenia …, 2007 - Elsevier
AIM: To assess the prevalence of Coronary Heart Disease (CHD) and Metabolic Syndrome (MS)
in patients treated with antipsychotics. METHODS: Retrospective, cross-sectional, …

Plant sterols and cardiovascular disease: a systematic review and meta-analysis

…, G De Backer, E Bruckert, R Carmena… - European heart …, 2012 - academic.oup.com
The impact of increased serum concentrations of plant sterols on cardiovascular risk is unclear.
We conducted a systematic review and meta-analysis aimed to investigate whether there …

The diabetogenic action of statins—mechanisms and clinical implications

DJ Betteridge, R Carmena - Nature Reviews Endocrinology, 2016 - nature.com
Abstract Treatment with statins has transformed primary and secondary prevention of
cardiovascular disease (CVD), including thrombotic stroke. Evidence-based data demonstrate the …

A comparison of schizophrenia outpatients treated with antipsychotics with and without metabolic syndrome: findings from the CLAMORS study

C Arango, J Bobes, P Aranda, R Carmena… - Schizophrenia …, 2008 - Elsevier
OBJECTIVE: To compare clinical, laboratory, lifestyle, and sociodemographic parameters
and cardiac risk in antipsychotic-treated patients with and without metabolic syndrome (MS). …

Prevalence, diagnosis, treatment, and control of hypertension in Spain. Results of the Di@ bet. es study

…, MA Prieto, E Bordiu, A Calle, R Carmena… - Revista Española de …, 2016 - Elsevier
Introduction and objectives Di@bet.es is a national study designed to estimate the prevalence
of diabetes mellitus and other cardiovascular risk factors in the Spanish adult population. …